公开(公告)号：US20170081385A1

公开(公告)日：2017-03-23

申请号：US15308535

申请日：2015-04-30

申请人： Emory University

发明人： Brantley R. Herrin ,  Max Dale Cooper ,  Rudolf Ehrhardt

IPC分类号： C07K14/725

CPC分类号： C07K14/7051 ,  C07K2319/30

摘要： This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant poly-peptide or variant disclosed herein to a subject in need thereof.

公开(公告)号：US11384134B2

公开(公告)日：2022-07-12

申请号：US16857130

申请日：2020-04-23

申请人： Emory University

发明人： Brantley R. Herrin ,  Max Dale Cooper ,  Rudolf Ehrhardt

IPC分类号： C07K14/46 ,  C12N15/00 ,  C07K14/725

摘要： This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

公开(公告)号：US10167330B2

公开(公告)日：2019-01-01

申请号：US15308535

申请日：2015-04-30

申请人： Emory University

发明人： Brantley R. Herrin ,  Max Dale Cooper ,  Rudolf Ehrhardt

IPC分类号： C07K14/705 ,  C07K14/725

摘要： This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

公开(公告)号：US20200308247A1

公开(公告)日：2020-10-01

申请号：US16857130

申请日：2020-04-23

申请人： Emory University

发明人： Brantley R. Herrin ,  Max Dale Cooper ,  Rudolf Ehrhardt

IPC分类号： C07K14/725

摘要： This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

公开(公告)号：US20190202887A1

公开(公告)日：2019-07-04

申请号：US16183340

申请日：2018-11-07

申请人： Emory University

发明人： Brantley R. Herrin ,  Max Dale Cooper ,  Rudolf Ehrhardt

IPC分类号： C07K14/725

CPC分类号： C07K14/7051 ,  C07K2319/30

摘要： This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.